Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash & Current Investments (2021 - 2025)

Historic Cash & Current Investments for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $344.0 million.

  • Amylyx Pharmaceuticals' Cash & Current Investments rose 4675.65% to $344.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $344.0 million, marking a year-over-year increase of 4675.65%. This contributed to the annual value of $176.5 million for FY2024, which is 5247.2% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Cash & Current Investments stood at $344.0 million, which was up 4675.65% from $180.8 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Cash & Current Investments high stood at $373.3 million for Q1 2024, and its period low was $96.1 million during Q4 2021.
  • Moreover, its 5-year median value for Cash & Current Investments was $282.5 million (2022), whereas its average is $270.0 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Cash & Current Investments skyrocketed by 26095.74% in 2022 and then tumbled by 5247.2% in 2024.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Cash & Current Investments stood at $96.1 million in 2021, then skyrocketed by 260.96% to $346.9 million in 2022, then rose by 7.04% to $371.4 million in 2023, then plummeted by 52.47% to $176.5 million in 2024, then soared by 94.89% to $344.0 million in 2025.
  • Its last three reported values are $344.0 million in Q3 2025, $180.8 million for Q2 2025, and $204.1 million during Q1 2025.